Abstract
Adding nevirapine to zidovudine and didanosine improved the long-term immunologic and virologic effects of therapy and was associated with severe rash among the patients studied, who had had extensive previous therapy. These results support 1) the continuing development of combinations of more than two antiretroviral drugs to increase and prolong HIV-1 suppression and 2) the potential utility of nevirapine in combination regimens.
Keywords
DidanosineZidovudineNevirapineMedicineInternal medicineGastroenterologyImmunologyAdverse effectReverse-transcriptase inhibitorLamivudineViral loadPlaceboVirologyPharmacologyViral diseaseVirusPathology
Affiliated Institutions
Related Publications
Update on prevention, diagnosis, and treatment of chronic hepatitis B
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jon...
Hepatocellular carcinoma
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cance...
Publication Info
- Year
- 1996
- Type
- article
- Volume
- 124
- Issue
- 12
- Pages
- 1019-1030
- Citations
- 291
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
291
OpenAlex
Cite This
Richard T. D’Aquila
(1996).
Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection.
Annals of Internal Medicine
, 124
(12)
, 1019-1030.
https://doi.org/10.7326/0003-4819-124-12-199606150-00001
Identifiers
- DOI
- 10.7326/0003-4819-124-12-199606150-00001